Moberg Pharma
在场
Moberg Pharma 是一家在股票代码 MOB (SE) 下上市的公司。
高管
查看带有其 10 名主要高管的组织结构图
Moberg Pharma 搜索最多的简介
- Anna Ljung, Chief Executive Officer
- Håkan Wallin, Director
- Kerstin Strinnholm, Executive Chairman of the Board
创建提醒
跟踪 Moberg Pharma 的高管变动
药店
Moberg Pharma 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Moberg Pharma 的最新新闻稿
- Moberg Pharma´s Interim report January - September 2024 | Moberg Pharma
- Moberg Pharma’s Nomination Committee appointed | Moberg Pharma
- Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients | Moberg Pharma
- Moberg Pharma´s interim report January - June 2024 | Moberg Pharma
- New number of shares and votes in Moberg Pharma AB (publ) | Moberg Pharma
- New number of shares and votes in Moberg Pharma AB (publ) | Moberg Pharma
- Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors – subscription rate in TO 2 of 98% | Moberg Pharma
- Subscription price for Moberg Pharma's warrants of series 2023:1 (TO 2) determined | Moberg Pharma
- The exercise period for Moberg Pharma's warrants of series 2023:1 (TO 2) begins today | Moberg Pharma
- The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024 | Moberg Pharma
- View more press releases Close
关于 Moberg Pharma 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Anna Ljung 
